FIELD: organic chemistry.
SUBSTANCE: group of inventions includes a compound of formula I, pharmaceutically acceptable salts, stereoisomers, individual compounds specified in the claim, a pharmaceutical composition containing them, and methods of treatment. In formula I R1 is (C1-C6)alkyl, -N(R5)(R6), or (C3-C6)cycloalkyl, where said (C3-C6)cycloalkyl is substituted with 0 or 1 a substituent which is (C1-C6)alkyl or (C1-C6)alkoxy; R5 and R6 each independently represent hydrogen or (C1-C6)alkyl, or R5 and R6 together with nitrogen to which they are attached form (4–8-membered) heterocycloalkyl, which is substituted with 0, 1 or 2 substitutes independently selected from the group consisting of (C1-C6)alkyl, halogen(C1-C6)alkyl and (C1-C6)alkoxy; R2 is N(R7)(R8), each of R7 and R8 is independently hydrogen or (C1-C6)alkyl, which is substituted with 0 or 1 substituent, which is halogen, (C1-C6)alkoxy, cyano or hydroxy; R3a is hydrogen or (C1-C3)alkyl substituted with 0 or 1 substituent, which is hydroxy or (C1-C3)alkoxy; R3b is hydrogen or (C1-C3)alkyl, provided that R3a and R3b are not both H when R4 is (R4-i); R4 is (R4-i) or (R4-ii); R4N is (C1-C6)alkyl, halogen(C1-C6)alkyl or (C3-C6)cycloalkyl; R4C is hydrogen, (C1-C6)alkyl, halogen(C1-C6)alkyl or (C1-C6)alkoxy; R4D is hydrogen, (C1-C6)alkyl, halogen(C1-C6)alkyl, halogen(C1-C6)alkoxy or (C3-C6)cycloalkyl, where said (C1-C6)alkyl and halogen(C1-C6)alkyl are substituted with 0 or 1 substituent, which is hydroxy or (C1-C6)alkoxy; R4E is hydrogen or (C1-C6)alkyl; R4F is hydrogen, halogen, (C1-C6)alkyl or halogen(C1-C6)alkyl, where said (C1-C6)alkyl and halogen(C1-C6)alkyl are substituted with 0 or 1 substitute, which is hydroxy, cyano or (C1-C6)alkoxy.
EFFECT: proposed are 2-(pyridin-2-yl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-1-one derivatives of formula I, having inhibitory activity on HPK1 kinase.
21 cl, 8 tbl, 300 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AZALACTAM COMPOUNDS AS HPK1 INHIBITORS | 2019 |
|
RU2801140C2 |
| CONDENSED TRICYCLIC BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | 2014 |
|
RU2689777C1 |
| SULFONAMIDE-CONTAINING BINDING SYSTEMS FOR MEDICINAL CONJUGATES | 2014 |
|
RU2729194C2 |
| (AZA)INDOLE-, BENZOTHIOPHENE- AND BENZOFURAN-3-SULPHONAMIDES | 2017 |
|
RU2767904C2 |
| CONDENSED DERIVATIVES OF IMIDAZOLE AND PYRAZOLE AS MODULATORS OF ACTIVITY TNF | 2014 |
|
RU2687093C1 |
| SUBSTITUTED BENZENE COMPOUNDS | 2013 |
|
RU2658919C2 |
| SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | 2019 |
|
RU2812726C2 |
| FUSED TRICYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | 2014 |
|
RU2679914C9 |
| NEW ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE AND PHOSPHODIESTERASE INHIBITORS WITH DUAL ACTION MECHANISM AND THEIR APPLICATION | 2018 |
|
RU2758373C2 |
| SERIN / TREONIN KINASE INHIBITORS FOR TREATING OF HYPEROPLIFERATIVE DISEASES | 2013 |
|
RU2644947C2 |
